About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

RaQualia Pharma Inc.(4579) Summary

4579
TSE Growth
RaQualia Pharma Inc.
333
JPY
-4
(-1.19%)
Apr 16, 12:38 pm JST
2.33
USD
Apr 15, 11:38 pm EDT
Result
PTS
outside of trading hours
333.9
Apr 16, 12:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.31
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
336 JPY 2.34 USD
Previous Close Apr 15
337 JPY 2.35 USD
High Apr 16, 9:01 am
338 JPY 2.36 USD
Low Apr 16, 12:35 pm
332 JPY 2.32 USD
Volume
17,500
Trading Value
6.00M JPY 0.04M USD
VWAP
335.33 JPY 2.35 USD
Minimum Trading Value
33,300 JPY 233 USD
Market Cap
7.27B JPY 0.05B USD
Number of Trades
59
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
Mid
1-Year Average
283
1-Year High Aug 30, 2024
2,310
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 0 933,400
Apr 4, 2025 0 1,042,500
Mar 28, 2025 0 1,047,300
Mar 21, 2025 0 1,044,600
Mar 14, 2025 0 1,060,500
Company Profile
RaQualia Pharma Inc. is a drug discovery venture company specializing in pain disorders. Its main revenue source is the out-licensing of intellectual property rights for drug candidates.
Sector
Pharmaceuticals
RaQualia Pharma Inc. is a research and development-oriented drug discovery venture with a business model focused on out-licensing intellectual property rights of novel drug candidates to pharmaceutical companies. The company conducts drug discovery research and development for high-need medical conditions, primarily in gastrointestinal and pain disorders. RaQualia Pharma Inc. pursues agile and flexible business activities, offering its entire research and development portfolio for out-licensing at various stages, from early exploration to clinical development. The company actively engages in open innovation-based research and development, addressing a wide range of disease areas through industry-academic collaborations. RaQualia Pharma Inc. has built a research and development portfolio comprising multiple projects, including out-licensing preparation programs, out-licensed programs, and collaborative research programs.